IQE Regulatory News (IQE)

15 Apr 2008 07:01

IQE PLC15 April 2008 IQE plc 15 April 2008 IQE plc (the 'Company') Additional Listing Application has been made to the London Stock Exchange for 994,657 ordinaryshares of 1p each in the Company ('Ordinary Shares') to be admitted to tradingon AIM. The Ordinary Shares are being issued pursuant to the exercise of shareoptions by certain employees under the IQE Group Share Option Scheme. TheOrdinary Shares are issued at the following prices: Price of issue Number of Ordinary SharesTotal at 1.000p 2,000Total at 5.633p 268,444Total at 6.533p 23,520Total at 6.670p 699,193Total at 8.000p 1,500TOTAL 994,657 Admission of these Ordinary Shares is expected to become effective on 18 April2008. Following this issue the total number of Ordinary Shares in issue will be432,037,854. Contacts: IQE plc +44 29 2083 9400Drew NelsonPhil RasmussenChris Meadows College Hill +44 20 7457 2020Adrian Duffield/ Ben Way Noble & Company Limited +44 20 7763 2200John Llewellyn-Lloyd/ Sam Reynolds Panmure Gordon (UK) Limited +44 20 7459 3600Aubrey Powell/ Ashton Clanfield NOTE TO EDITORS IQE plc is the leading global supplier of advanced semiconductor wafers withproducts that cover a diverse range of applications. It is able to provide a'one stop shop' for the wafer needs of the world's leading compoundsemiconductor manufacturers, who in turn use these wafers to make the chipswhich form the key components of virtually every high technology system. IQE hasparticular focus on the growing global wireless sector for applicationsincluding; mobile handsets, wireless infrastructure, Wi-Fi, WiMAX, basestations, GPS and satellite communications; as well as for the opticalcommunication sector including; optical storage (CD, DVD), laser optical mice,laser printers & photocopiers, thermal imagers, leading-edge medical products,bar-coding, high efficiency LEDs and advanced solar cells. The manufacturers of these chips are increasingly seeking to outsource waferproduction to specialist foundries such as IQE in order to reduce overall wafercosts and accelerate time to market. IQE is unique in being able to supplywafers using all of the leading crystal growth technology platforms includingMetal Organic Vapour Phase Epitaxy (MOVPE) and Molecular Beam Epitaxy (MBE) andthe Group is able to leverage its global purchasing volumes to reduce the costof raw materials. IQE also provides bespoke R&D services to deliver customized materials forspecific applications and offers specialist technical staff to manufacture tospecification either at its own facilities or on the customer's own sites. Thisis backed by a strategy of duplicating each key product processes over multiplesites to assure customers of security of supply as well as provide compellingcustomer benefits in terms of flexibility and predictability of cost, therebysignificantly reducing operating risk. IQE operates six manufacturing facilities; two in Cardiff and one in MiltonKeynes in the UK; two more in Bethlehem, Pennsylvania and Somerset, New Jerseyin the USA; and its most recent acquisition in Singapore. The Group also has 11sales offices located in major economic centres worldwide. This information is provided by RNS The company news service from the London Stock Exchange